D-cycloserine for Alzheimer's disease

Pauvlik JM Searle clinical research report. A two year, multicenter, randomized, double-blind controlled parallel group study of cycloserine in the treatment of Alzheimer's disease with six months placebo control Report No. EC6-93-06-025, July 30, 1993. Skokie, IL: GD Searle, 1993 1993

Fakouhi, 1995, Evaluation of cycloserine in the treatment of Alzheimer's disease, Journal of Geriatric Psychiatry and Neurology, 8, 226, 10.1177/089198879500800405

Mohr, 1995, Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease, Clinical Neuropharmacology, 18, 28, 10.1097/00002826-199502000-00004

Pauvlik JM Searle clinical research report. A two year, multicenter, randomized, double-blind controlled parallel group study of cycloserine in the treatment of Alzheimer's disease with six months placebo control Report No. NC6-93-06-009, September 29, 1993. Skokie, IL: GD Searle, 1993 1993

Schwartz, 1996, d-Cycloserine enhances implicit memory in Alzheimer patients, Neurology, 46, 420, 10.1212/WNL.46.2.420

Tsai, 1998, A preliminary study of D-cycloserine treatment in Alzheimer's disease, Journal of Neuropsychiatry and Clinical Neurosciences, 10, 224, 10.1176/jnp.10.2.224

Tsai, 1999, Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment., American Journal of Psychiatry, 156, 467, 10.1176/ajp.156.3.467

Randolph, 1994, D-cycloserine treatment of Alzheimer disease, Alzheimer Disease and Associated Disorders, 8, 198, 10.1097/00002093-199408030-00006

American Psychiatric Association, 1987, Diagnostic and statistical manual of mental disorders, III revised

American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders, IV

Bannerman, 1995, Distinct components of spatial learning revealed by prior training and NMDA receptor blockade, Nature, 378, 182, 10.1038/378182a0

Birks, 2000, Rivastigmine for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001191

Birks, 2006, Donepezil for dementia due to Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001190.pub2

Chessell, 1991, D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain., Brain Research, 565, 345, 10.1016/0006-8993(91)91668-Q

Clarke, 2003, Cochrane Reviewer's Handbook 4.2.0 [updated March 2003], The Cochrane Library

Folstein, 1975, "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6

Guy, 1976, ECDEU Assessment Manual for Psychopharmacology, US Dept Health, Education and Welfare Publication (ADM) 76-338, 2, 218

Jones, 1991, Effects of NMDA modulation in scopolamine dementia, Annals of the New York Academy of Sciences, 640, 241, 10.1111/j.1749-6632.1991.tb00226.x

Knopman, 1994, The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease, Neurology, 44, 2315, 10.1212/WNL.44.12.2315

Launer, 1999, Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses, Neurology, 52, 78, 10.1212/WNL.52.1.78

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of health and human services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Procter, 1989, Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease, Neuroscience Letters, 101, 62, 10.1016/0304-3940(89)90441-2

Rosen, 1984, A new rating scale for Alzheimer's disease, American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356

Turvey, 2000, Memory complaint in a community sample aged 70 and older, Journal of the American Geriatrics Society, 48, 1435, 10.1111/j.1532-5415.2000.tb02634.x

Wesnes, 1992, The cognitive drug research computerized assessment systems for elderly, AAMI and demented patients, Journal of Psychopharmacology, 6, 108, 10.1177/026988119200600135

World Health Organisation (WHO), 1991, ICD-10. Tenth revision of the International Classification of Diseases. Chapter V (F): Mental and Behavioural disorders (including psychological development). Clinical descriptions and diagnostic guidelines, Mental and behavioural disorders. Clinical descriptions and diagnostic guidelines

Jones, 2002, D-cycloserine for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003153